Torcetrapib: Difference between revisions
m (Protected "Torcetrapib": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 27: | Line 27: | ||
{{CMG}} | {{CMG}} | ||
'''Torcetrapib''' (CP-529414) was a [[medication|drug]] developed by Pfizer to treat [[hypercholesterolemia]] (elevated [[cholesterol]] levels) and prevent [[cardiovascular disease]]. Its development was halted when the drug was associated with off target toxicity including an increase in [[blood pressure]] and adverse effects on the [[aldosterone]] axis. | '''Torcetrapib''' (CP-529414) was a [[medication|drug]] developed by Pfizer to treat [[hypercholesterolemia]] (elevated [[cholesterol]] levels) and prevent [[cardiovascular disease]]. Its development was halted when the drug was associated with off target toxicity including an increase in [[blood pressure]] and adverse effects on the [[aldosterone]] axis. | ||
Latest revision as of 16:59, 20 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Torcetrapib (CP-529414) was a drug developed by Pfizer to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted when the drug was associated with off target toxicity including an increase in blood pressure and adverse effects on the aldosterone axis.
Mechanism
Torcetrapib is a cholesterylester transfer protein (CETP) inhibitor. This inhibition results in higher HDL cholesterol levels and reduces LDL cholesterol levels. Torcetrapib development began around 1990. The drug was first administered to humans in 1999. Manufacturing at production scale began in Ireland in 2005.[1]
Development and research
Pfizer had previously announced that torcetrapib would be sold in combination with Pfizer's statin, atorvastatin (Lipitor); however, following media and physician criticism, Pfizer had subsequently planned for torcetraipib to be sold independently of Lipitor.[2]
A 2004 trial showed that torcetrapib could increase HDL and lower LDL with and without an added statin.[3]
End of study
On December 2 2006 Pfizer discontinued the pivotal phase III trial evaluating torcetrapib's safety and efficacy because of an increase in mortality and cardiovascular events associated with the drug's use.[4]
The cost of advancing the development of the drug to Phase III was over 800 million dollars.[5]
References
- ↑ "Pfizer Begins Production at Torcetrapib/Atorvastatin Manufacturing Facility" (Press release). Pfizer. June 22 2005. Retrieved 2006-12-03. Check date values in:
|date=(help) - ↑ Berenson, Alex (July 26 2006). "Heart Pill to Be Sold by Itself". Business. The New York Times. Retrieved 2006-12-03. Check date values in:
|date=(help) - ↑ Brousseau, ME (April 8 2004). "Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol". New England Journal of Medicine. 350 (15): 1505&ndash, 1515. PMID 15071125. Retrieved 2006-12-03. Unknown parameter
|coauthors=ignored (help); Check date values in:|date=(help) - ↑ Berenson, Alex (December 3 2006). "Pfizer Ends Studies on Drug for Heart Diseas". The New York Times. Retrieved 2006-12-03. Check date values in:
|date=(help) (registration required) - ↑ Cutler, D. M. (2007-03-29). "The Demise of the Blockbuster?" (HTML). The New England Journal of Medicine. Massachusetts Medical Society. 356: 1292–1293. ISSN: 1533-4406. Retrieved 2007-04-23. Check date values in:
|date=(help)